1. Sheng-Chieh Chou, Yu-Chen Hsu, Shu-Wha Lin. Gene Therapy for Hemophilia, A Clinical Viewpoint. Journal of the Formosan Medical Association 122, 2023. 1101e1110. https://doi.org/10.1016/j.jfma.2023.05.008
2. Sanchez NA, Brissia L. Gene therapy for hemophilia: Current status and future perspective. GSC Advanced Research and Reviews, 2023, 15(03), 295–303. https://doi.org/10.30574/gscarr.2023.15.3.0192
3. Miesbach W, Klamroth R, Oldenburg J, Tiede A: Gene therapy for hemophilia—opportunities and risks. Dtsch Arztebl Int 2022; 119: 887–94. DOI: 10.3238/arztebl.m2022.0353
4. Mazepa MA, Monahan PE, Baker JR, Riske BK, Soucie JM: Men with severe hemophilia in the United States: birth cohort analysis of a large national database. Blood 2016; 127: 3073–81. Doi: 10.1182/blood-2015-10-675140.
5. Hoots WK, Lewandoska M. Gene Therapy and Investigational Approaches for Hemophilia. UpToDate, 2023. https://www.uptodate.com/ contents/gene-therapy-and-investigational-approaches-for-hemophilia
6. Nathwani AC. Gene Therapy for hemophilia. Hematology Am Soc Hematol Educ Program. 2019 (1):1. DOI: 10.1182/hematology.2022000388
7. Pipe SW. Delivering on the promise of gene therapy for haemophilia. Haemophilia. 2021;27 Suppl 3:114. doi: 10.1111/hae.14027.
8. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirusassociated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365: 2357–65. doi: 10.1056/NEJMoa1108046.
9. Nathwani AC, Reiss U, Tuddenham E, et al. Adeno-associated mediated gene transfer for hemophilia B:8 year follow up and impact of removing “empty viral particles” on safety and efficacy of gene transfer. Blood 2018; 132 (Suppl. 1): 491. DOI:10.1182/blood-2018-99-118334.
10. Miesbach W, Meijer K, Coppens M, et al. Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B. Blood 2018; 131: 1022–31. doi: 10.1182/blood-2017-09-804419.
11. Miesbach W, Meijer K, Coppens M, et al. Five year data confirms stable FIX expression and sustained reductions in bleeding and factor IX use following AMT-060 gene therapy in adults with severe or mode - rate-severe hemophilia B. Abstract. Res Pract Thromb Haemost. 2021; 5 (Suppl. 2).
12. Soroka AB, Feoktistova SG, Mityaeva ON, Volchkov PY. Gene Therapy Approaches for the Treatment of Hemophilia B. Int J Mol Sci. 2023 Jun 28;24(13):10766. doi: 10.3390/ijms241310766.
13. Samelson-Jones BJ, Finn JD, George LA, Camire RM, Arruda VR. Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity. JCI Insight 2019; 5: e128683. Doi:10.1172/jci.insight.128683
14. von Drygalski A, Giermasz A, Castaman G, et al. Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. Blood Adv 2019; 3: 3241–7. doi: 10.1182/bloodadvances. 2019000811.
15. Miesbach W, Leebeek FWG, Recht M, et al. Final analysis from the pivotal phase 3 hope-B gene therapy trial: stable steady-sate efficacy and safety of etranacogene dezaparvovec in adults with severe or moderately severe haemophilia B. Haemophilia 2022; 28, S1, Special Issue: 15th Annual Congress of European Association for Haemophilia and Allied Disorders 2022, 2–4 February 2022, Virtual Meeting Presentation: 99–100.
16. Fidanacogene Elaparvovec (Beqvez). CADTH Reimbursement Recommendation: Indication: For the treatment of adults (aged 18 years or older) with moderately severe to severe hemophilia B (congenital Factor IX deficiency) who are negative for neutralizing antibodies to variant AAV serotype Rh74. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Mar. https://www.ncbi.nlm.nih.gov/books/NBK602912/
17. Rangarajan S, Walsh L, Lester W, et al. AAV5–factor VIII gene transfer in severe hemophilia A. N Engl J Med 2017; 377: 2519–30. DOI:10.1056/NEJMoa1708483
18. Pasi KJ, Rangarajan S, Mitchell N, et al. Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for haemophilia A. N Engl J Med 2020; 382: 29–40. DOI:10.1056/NEJMoa1908490
19. Pasi KJ, Laffan M, Rangarajan S, et al. Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A. Haemophilia 2021; 27: 947–56. Doi: 10.1111/hae.14391.
20. Laffan M, Rangarajan S, Lester W, et al. Hemostatic results for up to 6 years following treatment with valoctocogene roxaparvovec, an AAV5-hFVIII-SQ gene therapy for severe hemophilia A. 2023. www.abstracts.isth.org/abstract/hemostatic-results-for-up-to-6-years-following-treatment-with-valoctocogene-roxaparvovec-an-aav5-hfviii-sq-genetherapy- for-severe-hemophilia-a/.
21. Ozelo MC, Mahlangu J, Pasi KJ, et al. Valoctocogene roxaparvovec gene therapy for hemophilia A. N Engl J Med 2022; 386: 1013–25. DOI:10. 1056/NEJMoa2113708
22. Mahlangu J, kaczmarek R, et al. Two-year otucomes of valactocogene roxaparvovec therapy for hemophilia A. N Eng J Med 2023;388:694-705. DOI: 10.1056/NEJMoa2211075.
23. George LA, Monahan PE, Eyster ME, et al. Multiyear factor VIII expression after AAV gene transfer for hemophilia A. N Engl J Med 2021; 385: 1961–73. DOI: 10.1056/NEJMoa2104205
24. Thornburg CD. Etranacogene dezaparvovec for hemophilia B gene therapy. Ther Adv Respir Dis 2021;2: 26330040211058896. doi: 10.1177/26330040211058896
25. Fong S, Yates B, Sihn CR, Mattis AN, Mitchell N, Liu S, et al. Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A. Nat Med 2022;28(4):789-97. doi: 10.1038/s41591-022-01751-0.
26. Chowdary P, Shapiro S, Makris M, Evans G, Boyce S, Talks K, et al. Phase 1-2 trial of AAVS3 gene therapy in patients with hemophilia B. N Engl J Med 2022;387(3):237-47. doi: 10.1056/NEJMoa2119913.
27. George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson- Jones BJ, Ducore J, et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med 2017; 377(23):2215-27.DOI: 10.1056/NEJMoa1708538
28. Donsante A, Vogler C, Muzyczka N, Crawford JM, Barker J, Flotte T, et al. Observed incidence of tumorigenesis in longterm rodent studies of rAAV vectors. Gene Ther 2001;8(17):1343-6. doi: 10.1038/sj.gt.3301541.
29. Gil-Farina I, Fronza R, Kaeppel C, Lopez-Franco E, Ferreira V, D’Avola D, et al. Recombinant AAV integration is not associated with hepatic genotoxicity in nonhuman primates and patients. Mol Ther 2016;24(6):1100-5. doi: 10.1038/mt.2016.52.
30. Pipe Steven W, Recht Michael, Key Nigel S, Leebeek Frank WG, Castaman Giancarlo, Lattimore Susan U, et al. First data from the phase 3 HOPE-B gene therapy trial: efficacy and safety of etranacogene dezaparvovec (AAV5-Padua hFIX variant; AMT- 061) in adults with severe or moderate-severe hemophilia B treated irrespective of pre-existing anti-capsid neutralizing antibodies. 62nd ASH; December 8, 2020 Blood 2020.
31. Leborgne C, Barbon E, Alexander JM, Hanby H, Delignat S, Cohen DM, et al. IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies. Nat Med 2020;26(7):1096e101. doi: 10.1038/s41591-020-0911-7.